Also of interest that none of the buyers were their corporate partners
There are two reasons for this:
1. Japanese pharmas didn't have many partnership in oncology with US companies before. So, they didn't have the chance to buy their partners from the past. They have a few partnership now.
2. There are very few high quality non-partnered oncology drugs out there. Japanese pharmas paid premium prices for these buyout, so the quality they chose were quite high.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.